Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site

Thrombosis and Haemostasis

Volumn 92, Issue 3, 2004, Pages 522-528

  Pratt, Kathleen P ^a   Qian, Jiahua ^b,e   Ellaban, Ekram ^b   Okita, David K ^c   Diethelm Okita, Brenda M ^c   Conti Fine, Bianca ^c   Scott, David W ^b,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HOLLAND LABORATORY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

C2 domain; Factor VIII; T cell epitopes

Indexed keywords

BLOOD CLOTTING FACTOR 8C; BLOOD CLOTTING INHIBITOR; CD4 ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HEMOPHILIA A; HYDROPHOBICITY; MEMBRANE BINDING; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; CELL MEMBRANE; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FACTOR VIII; HEMOPHILIA A; IMMUNODOMINANT EPITOPES; MICE; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES; VON WILLEBRAND FACTOR;

EID: 4544254511     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH03-12-0755     Document Type: Article

References (43)

1. van Dieijen G, et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
2. Pemberton S, et al. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-21.
3. Liu ML, et al. A domain mutations in 65 haemophilia A families and molecular modeling of dysfunctional factor VIII proteins. Br J Haematol 1998; 103: 1051-60.
4. Fuentes-Prior P, et al. New insights into binding interfaces of coagulation factors V and VIII and their homologues. Lessons from high resolution crystal structures. Curr Protein Pept Sci 2002; 3: 313-39.
5. Pratt KP, et al. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature 1999; 402: 439-42.
6. Gilbert GE, et al. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-81.
7. Liu ML, et al. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000; 96: 979-87.
8. Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost 2003; 29: 11-22.
9. Antonarakis SE, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-12.
10. Schwaab R, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
11. Scandella D, et al. Epitope specificity and functional characterization of factor VIII inhibitors. Adv Exp Med Biol 1995; 386: 47-63.
12. Goodeve AC, et al. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost 2000; 83: 844-8.
13. Goodeve AC, Peake IR. The molecular basis of hemophilia a: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003; 29: 23-30.
14. Tuddenham EG, Schwaab R, Seehafer J, et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22: 3511-33.
15. Scandella D, et al. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6.
16. Scandella D, et al. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-26.
17. Scandella D, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-9.
18. Scandella DH, et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res 2001; 101: 377-85.
19. Saenko EL, et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002; 8: 1-11.
20. Shima M, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epiitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-6.
21. Shima M, et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol 1995; 91: 714-21.
22. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
23. Newton-Nash DK, Tollerud D, Guevarra L, et al. Interferon-gamma secretion defects in haemophilia A patients receiving highly purified plasma-derived or recombinant factor VIII. Br J Haematol 1996; 95: 554-60.
24. Singer ST, et al. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
25. Reding MT, Wu H, Krampf M, et al. CD4+ T-cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
26. Reding MT, Wu H, Krampf M, et al. Sensitization of CD4+ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
27. Reding MT, Lei S, Lei H, et al. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 568-75.
28. Reding MT, Okita DK, Diethelm-Okita BM, et al. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003; 1: 1777-84.
29. Hu GL, Okita DK, Diethelm-Okita B, et al. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003; 1: 2159-66.
30. Wu H, Reding M, Qian J, et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-33.
31. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, et al. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-19.
32. Takeshima K, Smith C, Tait J, et al. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003; 89: 788-94.
33. Stern U, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215-21.
34. + cells of myasthenia gravis patients and healthy subjects. J Clin Invest 1994; 93: 1020-8.
35. Manfredi AA, Protti MP, Dalton MWM, et al. Myasthenia Gravis: T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits. J Clin Invest 1993; 92: 1055-67.
36. + T cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects. Eur J Immunol 1995; 25: 3207-14.
37. + cells on tetanus and diphtheria toxins. J Infect Dis 2000; 181: 1001-9.
38. Wang ZY, Okita DK, Howard JF, et al. T cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 1998; 50: 1045-54.
39. Healey JF, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-9.
40. Barrow RT, Healey JF, Gailani D, et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 564-8.
41. Barrow RT, Healey JF, Jacquemin MG, et al. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 2001; 97: 169-74.
42. Rawle FEM, Labelle AD, Postma L, et al. Oral administration of factor VIII contributes to the prevention of anti-factor VIII antibody development after protein infusion, and prolongs factor VIII transgene expression post-adenoviral gene transfer. Blood 2003; 102: abstract #566.
43. Brown BD, Shi CX, Rawle FE, et al. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost 2004; 2: 111-8.